Ovarian Cancer Still Found Late, Womb Cancer Rising: Gynaecological Cancer Data

Around 1.44 million women worldwide were estimated to have been diagnosed with a gynaecological cancer in 2024, and about 610,000 died of one. Behind that total sit five different cancers with different stories: cervical cancer is largely preventable, womb cancer is becoming more common in many countries, and ovarian cancer is still diagnosed late more often than not, with no screening test that has been shown to reduce deaths.

For the women diagnosed, and for the partners, daughters and friends beside them, these are not abstract categories. A gynaecological cancer often means intimate examinations, surgery that can affect fertility and identity, and, for ovarian cancer especially, a diagnosis that may arrive after weeks of symptoms that are easy to put down to something else. This article sets out what international data show about how common each cancer is, how survival compares, why ovarian cancer is so often found late, and what the evidence asks of health services.

Five cancers, five different patterns

The International Agency for Research on Cancer's GLOBOCAN 2024 estimates, published in 2026, give the most recent worldwide picture^[1]. Cervical cancer is the most common gynaecological cancer, with an estimated 604,196 new cases and 279,583 deaths: the fifth most commonly diagnosed cancer in women and the fourth leading cause of cancer death among women. Cancer of the corpus uteri (the body of the womb, mostly endometrial cancer) follows with 434,620 new cases and 100,680 deaths. Ovarian cancer accounts for 330,731 new cases and 203,850 deaths. Vulval and vaginal cancers are rarer, at 48,894 and 18,143 new cases^[1].

The ratio of deaths to new cases is what sets ovarian cancer apart. Worldwide, womb cancer had roughly one death for every four new diagnoses in 2024; ovarian cancer had roughly three deaths for every five. An editorial published alongside the GLOBOCAN report describes this as "one of the highest mortality‑to‑incidence ratios of any solid tumor"^[3]. A ratio like this is a rough signal, not a survival figure: the deaths in a given year are mostly among women diagnosed in earlier years.

Rates are age-standardised to the world standard population. Source: GLOBOCAN 2024, Tables 1 and 2 in Sung et al.^[1]

These are modelled estimates. The same editorial points out that only about one country in three supplies high-quality incidence data, and that ovarian cancer is especially hard to count: it is several distinct diseases, some registries now record tumours starting in the fallopian tube separately (producing "apparent declines" in ovarian incidence in some places), and subtypes such as clear cell carcinoma make up a substantially larger share of cases in East Asia than in Western populations^[3].

Ovarian cancer: most women are diagnosed after it has spread

Late diagnosis is the defining problem in ovarian cancer data. The CA editorial puts the share of women presenting with advanced-stage disease at about 80%, "often after months of nonspecific symptoms", citing a clinical review rather than registry data^[3]. Registries, which record stage differently, still show most women in high-income countries diagnosed after the cancer has spread. In the International Cancer Benchmarking Partnership (ICBP) SURVMARK-2 study of 58,161 women diagnosed in 2010 to 2014 in Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK, most were diagnosed at "distant" stage, from 64% in Canada to 71% in Norway^[4]. In the United States, 49% of ovarian cancers were diagnosed at distant stage in 2018 to 2022, down from 57% a decade earlier^[5].

Stage matters enormously. For women diagnosed in the US in 2015 to 2021, five-year relative survival was 92% when the cancer was found at a localised stage, 71% at a regional stage and 32% at a distant stage^[5]. Across all stages, US five-year relative survival rose from 36% for diagnoses in 1975 to 1977 to 52% for diagnoses in 2015 to 2021, and ovarian cancer death rates fell by 2.7% a year over the decade to 2023, which the authors say likely reflects small gains in survival for advanced disease and a shift towards earlier diagnosis^[5].

Between countries, the gap is widest for older women. In SURVMARK-2, three-year net survival for all ages ranged from 45% to 57%, highest in Norway (57%) and Australia (56%). For women aged 75 and over with distant-stage disease it ranged from 12% in Ireland to 24% in Norway: a twofold difference for the same stage of the same cancer^[4]. The authors point to differences in access to and quality of treatment and in other health conditions among older women as the questions to investigate. Survival figures describe women diagnosed years ago and say nothing about any individual woman's outlook; how stage shapes outcomes across cancers is covered in stage at diagnosis.

Up to almost half of ovarian cancers are found after an emergency admission

One measure of how late a cancer is found is how often it is diagnosed after an emergency hospital admission rather than a planned referral. An ICBP study of 857,068 people diagnosed with eight cancers in 2012 to 2017, across 14 jurisdictions in Australia, Canada, Denmark, New Zealand, Norway and the UK, found that the share of ovarian cancers diagnosed within 30 days of an emergency admission ranged from 20.6% in Denmark to 48.1% in New Zealand, with Scotland (42.8%), Wales (40.8%) and England (34.8%) towards the higher end^[2]. Jurisdictions defined emergency presentation in slightly different ways, which accounts for some of the spread.

The pattern is linked to outcomes. Across jurisdictions, a 10 percentage point higher share of emergency presentations was associated with 2.5% lower one-year net survival for ovarian cancer^[2]. The authors note that ovarian, lung and colon cancer often present with non-specific symptoms and are associated with high proportions of several primary care consultations before diagnosis. That points to the design of diagnostic pathways, not to women "leaving it too late". The wider evidence on routes to diagnosis is set out in from first symptom to diagnosis.

Population surveys suggest public awareness is patchy. In a UK telephone survey of 1,000 women using the Ovarian Cancer Awareness Measure, 58% could not name any symptom of ovarian cancer unprompted, although 99% recognised at least one when given a list; recognition was lowest for symptoms related to eating and feeling full^[6]. In an ICBP survey of 1,043 women over 50 in Wales, symptoms related to eating difficulties and changes in bladder or bowel habits were recognised by fewer than half, and lower awareness was associated with older age, lower education and being single^[7]. These are population findings about knowledge, not a guide to what any symptom means for an individual; anyone worried about their own health should speak to a health professional.

Screening the general population has not been shown to reduce ovarian cancer deaths

Because stage matters so much, a screening test that finds ovarian cancer earlier has long been sought. The largest trial, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), randomly allocated postmenopausal women aged 50 to 74 in England, Wales and Northern Ireland, recruited in 2001 to 2005, to annual multimodal screening (MMS), annual transvaginal ultrasound, or no screening; 202,562 were included in the analysis^[8].

After a median follow-up of 16.3 years, multimodal screening did shift stage: the incidence of stage I disease was 47.2% higher and of stage IV disease 24.5% lower than with no screening. But this did not translate into a significant reduction in deaths. Deaths from ovarian and tubal cancer were 296 of 50,625 women (0.6%) in the multimodal group, 291 of 50,623 (0.6%) in the ultrasound group and 619 of 101,314 (0.6%) with no screening. Neither form of screening produced a statistically significant reduction in deaths (p=0.58 and p=0.36). The investigators concluded that "general population screening cannot be recommended"^[8]. Finding cancers at an earlier stage is not the same as preventing deaths.

UKCTOCS excluded women at raised familial risk. Inherited risk from BRCA1, BRCA2 and Lynch syndrome, which affects both ovarian and womb cancer, is covered in inherited cancer risk.

Womb cancer is rising in many countries, and the rise is not shared equally

Womb cancer usually has better survival than ovarian cancer, but it is becoming more common. A 2026 study of registry data for women aged 30 to 84 in 24 countries found that incidence rose between 1998 and 2017 in 13 of them, fastest in Thailand (3.58% a year), Belarus (3.32%) and Türkiye (3.01%). It fell in Austria and Finland and was stable in nine^[9]. Increases were steepest among women aged 30 to 34, above 5% a year in Thailand and the United Kingdom. In the UK, after allowing for age and period, women born around 1983 had 3.45 times the incidence of those born around 1953. Birth cohort effects in 10 of the 13 countries with rising rates suggest that risk is changing from one generation to the next^[9]. In Taiwan, registry data show age-standardised womb cancer incidence rising from 2.91 to 17.42 per 100,000 women between 1995 and 2022, while cervical cancer fell from 20.06 to 6.78^[10]. In the Nordic countries, incidence among women under 50 rose by 36% between 1998 to 2000 and 2021 to 2023, from 1.4 to 1.9 per 100,000 person-years^[11]. These studies use different methods and age ranges and are not directly comparable.

In the United States the rise reaches deaths as well as diagnoses. Uterine corpus cancer death rates rose by 1.6% a year from 2014 to 2023, continuing a 26-year trend^[5]. Five-year relative survival fell from 84% to 81% over two decades, which the American Cancer Society authors link to a rising share of more aggressive non-endometrioid subtypes, up from 9% in the mid-1990s to 21% in 2015 to 2021. Obesity and reproductive factors are associated with womb cancer risk and likely contribute to the rise, though less so for the non-endometrioid subtypes driving it^[5]. These associations describe populations; they do not explain any one woman's diagnosis.

The inequality is stark. Black women in the US have uterine corpus cancer death rates about twice those of other women. Only 56% of their womb cancers are diagnosed at a localised stage, against 71% for White women, and five-year relative survival is 63% against 85%^[5]. The same report finds Black women have up to twice the risk of White women of not receiving guideline-concordant diagnostic evaluation for womb cancer, and names less access to high-quality care, with more aggressive disease explaining only a small part, as the largest contributor to the wider survival gap between Black and White people in the US^[5].

Cervical, vulval and vaginal cancers: prevention gaps and rarer diseases

Cervical cancer is the leading cause of cancer death in women in 26 countries, mostly in sub-Saharan Africa but also in parts of Central and South America, Melanesia and South-Eastern Asia. Incidence varies about eightfold between world regions. Age-standardised mortality is almost twice as high in transitioning as in transitioned countries (8.3 against 4.3 per 100,000)^[1]. Women living with HIV make up 6% of women newly diagnosed worldwide, and 64% in Southern Africa^[1]. WHO's elimination strategy defines elimination as 4 or fewer new cases per 100,000 women a year, with 2030 targets of 90% of girls vaccinated against HPV by age 15, 70% of women screened by 35 and again by 45, and 90% of women with precancer or cancer treated^[12]. The evidence on HPV vaccination and cervical cancer is set out in depth in the HPV vaccine and cervical cancer.

Vulval and vaginal cancers are rare, and the evidence on them is thin: GLOBOCAN estimates 18,868 and 7,484 deaths worldwide in 2024^[1]. They mainly affect older women. In one Italian population registry (Reggio Emilia, 1996 to 2021, 328 women), median age at diagnosis was 76.1 years for vulval cancer and 70.2 for vaginal cancer, and five-year relative survival was 63% and 44%^[13]. Larger international studies of these cancers are scarce.

What the evidence asks of us

• Design diagnostic pathways for vague symptoms. With no screening test shown to reduce ovarian cancer deaths^[8], earlier diagnosis depends on how quickly health systems investigate non-specific symptoms. Emergency diagnosis rates that range from about one in five to almost one in two across comparable countries^[2] show that pathways, not women, are the variable that services can change.
• Close the treatment gap for older women. The twofold difference in survival for older women with advanced ovarian cancer between Ireland and Norway^[4] calls for audit of who is offered specialist surgery and treatment, and why.
• Fund research on a growing cancer. Rising womb cancer incidence among younger generations in many countries^[9] and rising US death rates^[5] make the causes, prevention and treatment of aggressive subtypes a research priority.
• Measure and act on inequality. Gaps in diagnostic evaluation, stage and survival for Black women with womb cancer in the US^[5] are gaps in care. Registries need data on ethnicity, deprivation, stage and treatment to see such gaps everywhere; the GLOBOCAN editorial notes that most registries lack individual-level socioeconomic data and fewer still capture stage or treatment, with the gap widest in low- and middle-income countries^[3].
• Deliver the cervical cancer elimination targets. WHO's 90–70–90 targets for vaccination, screening and treatment by 2030^[12] are the clearest route to ending the deaths that still fall hardest on women in sub-Saharan Africa and on women living with HIV^[1].
• Do not forget the rarer cancers. Vulval and vaginal cancers need pooled international data so that the women affected have evidence to rely on.

The section overview is at the cancer research library.

Language: this piece says "people with cancer" and "people living with and after cancer", and describes the illness and its treatment plainly, without combat metaphors. Clinical terms such as "stage", "incidence" and "net survival" are used in the sense the cited source defines them.

Why we're publishing this

Gynaecological cancer charities, support groups and clinicians have argued that ovarian cancer is diagnosed too late, that womb cancer deserves more attention as it becomes more common, and that cervical cancer deaths are a measure of unequal access to prevention. The data support each of those cases. We have brought the latest international figures together, kept each cancer's numbers separate and linked each to its source, so that the organisations supporting women with these cancers can cite them with confidence.

How to read this data

GLOBOCAN figures are modelled estimates for 2024 built from registry and mortality data of uneven quality, much of it collected before 2020; they are least certain where registry coverage is thinnest^[3]. Incidence and mortality rates in the table are age-standardised; case and death counts are not, and the two should not be compared directly. Survival figures are relative or net survival, which estimate survival from the cancer itself, and describe women diagnosed years ago (2010 to 2014 in the ICBP study, 2015 to 2021 in the US data). The ICBP emergency presentation figures used two slightly different definitions. UKCTOCS is a randomised trial, the strongest design for judging screening, but it tested two specific approaches in women at average risk in the UK. Evidence from low- and middle-income countries on ovarian and womb cancer survival is limited, and vulval and vaginal cancer evidence is sparse everywhere. Some figures here are our own simple calculations from published totals (the combined worldwide total and the death-to-case ratios); everything else is as published.

Use this data

Free to cite with attribution to Better Health For Everyone. Charities, campaigners and journalists are welcome to reuse these figures and charts. For the underlying figures as a spreadsheet, get in touch.

Important: This article summarises published research for general information. It is not medical advice and cannot be used to diagnose, treat or predict anything about an individual. If you have concerns about your own or someone else's health, please speak to a qualified health professional.

Sources

1. Sung H, Filho AM, Laversanne M, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA: A Cancer Journal for Clinicians, 2026. europepmc.org/article/PMC/PMC13343830
2. McPhail S, Swann R, Johnson SA, et al. Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study. Lancet Oncology, 2022. europepmc.org/article/PMC/PMC9046095
3. Washington CR, Moore KN, Ray-Coquard IL. Accurate data as the foundation of equitable cancer control: lessons from global cancer statistics 2024 and the complexity of ovarian cancer. CA: A Cancer Journal for Clinicians, 2026. europepmc.org/article/PMC/PMC13377952
4. Cabasag CJ, Butler J, Arnold M, et al. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): a population-based study. Gynecologic Oncology, 2020. europepmc.org/article/MED/32005583
5. Siegel RL, et al. Cancer statistics, 2026. CA: A Cancer Journal for Clinicians, 2026. europepmc.org/article/PMC/PMC12798275
6. Low EL, Waller J, Menon U, et al. Ovarian cancer symptom awareness and anticipated time to help-seeking for symptoms among UK women. Gynecologic Oncology, 2013. europepmc.org/article/MED/23709609
7. Brain KE, Smits S, Simon AE, et al. Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample. BMC Cancer, 2014. europepmc.org/article/PMC/PMC3975332
8. Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The Lancet, 2021. europepmc.org/article/MED/33991479
9. Kelly KP, Felix AS, Jiang C, Rosenberg PS, Jemal A, Sung H. Trends in incidence rates of uterine corpus cancer by birth cohort in 24 countries, 1998-2017. Journal of the National Cancer Institute, 2026. europepmc.org/article/MED/42872484
10. Chang Y, Kay N, Chiu LC, et al. Incidence trends and geographic variations of corpus uteri and cervical cancer in Taiwan, 1995-2022: a population-based study. Cancers (Basel), 2026. europepmc.org/article/PMC/PMC12985120
11. Riese C, Chen EY, Nilsson H, et al. Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old). Gynecologic Oncology, 2026. europepmc.org/article/MED/42617581
12. World Health Organization. Cervical cancer: fact sheet. WHO, 2026. who.int/news-room/fact-sheets/detail/cervical-cancer
13. Bisceglia I, Marinelli F, Mandato VD, et al. Incidence and survival of vulvar and vaginal cancers in a province of Northern Italy: a population-based study. Gynecologic Oncology Reports, 2025. europepmc.org/article/PMC/PMC12550708